Brand name : Pomahope
Active ingredient : Pomalidomide
Manufactured : Abbott
Strength : 3mg
Pack : 21 capsules in a container
Category : Anti-neoplastic drug
Pomahope 3mg is a Glenmark Pharmaceuticals product which is endorsed by FDA, containing an active anti-cancer drug called Pomalidomide.
Pomahope 3mg is available as orally bioavailable thalidomide derivative with various therapeutic activities such as;
Pomahope 3mg is like thalidomide & Lenalidomide with related to decreased rate of serum aminotransferase elevations during treatment.
This may lead to severe liver injury.
Pomahope 3mg is involved in the treatment for regression & unmanageable multiple myeloma.
Pomahope 3mg is used in the patients who are failing to response for Lenalidomide treatment.
Pomahope 3mg is used in combination with dexamethasone.
The major therapeutic indication of Pomahope 3mg is involved in the treatment of multiple myeloma.
This treatment is occurred by combining with dexamethasone for reducing the side effect associated with Pomahope 3mgomide.
Pomahope 3mg is majorly indicated in patients who are not reacts for prior two therapies like Lenalidomide & proteasome inhibitor.
DOSAGE & ADMINISTRATION
The prescribed dose of Pomahope in multiple myeloma is 4mg should be administered orally as once a day on day 1 to 21 of reciprocated 28-day cycles.
Pomahope 3mg should be concomitant with dexamethasone.
Pomahope 3mg Capsules should be taken with or without food.
During hematological toxicities:
ANC (absolute neutrophils count) <500/mcl: Postpone the Pomahope therapy and provide CBC weekly
ANC more than or equal to 500/mcl: Continue the Pomahope 3mg daily.
Platelets count <25,000/mcL: postpone the Pomahope treatment & follow the CBC
>50,000/mcL: continue 3mg of Pomahope
Pomahope 3mg with potent CYP1A2 inhibitor:
During this combination reduce the dose of Pomahope by 50%
In renal impairment:
Initial dose of Pomahope is 3mg
In hepatic impairment:
Mild to moderate condition, an initial dose of Pomahope is 3mg; in severe condition, the initial dose of Pomahope is 2mg.
Pomahope 3mg exhibits various activities like;
Promote apoptosis of hematopoietic cancer cells
Co adjuvant with dexamethasone in both Lenalidomide sensitive & resistant myeloma cells to activate the tumor cell apoptosis
Boosted the T-cells & natural killer cell mediate immunity.
The drug is prohibited the formation of pro-inflammatory cytokines by monocytes.
Interfere with formation of new vessels and leads to inhibit the cell division.
There are two major worsening condition may occur during the treatment using with Pomahope 3mg.
Embryo fetal damage :
Pomahope 3mg Capsules are contraindicated to pregnancy period.
During the treatment, patients avoid to becoming pregnant.
Use effective contraceptives for preventing pregnancy during therapy.
Venous & arterial thromboembolism :
Patient who are receiving Pomahope 3mg Capsules have chance of getting deep vein thrombosis, pulmonary embolism, myocardial infarction & stroke.
This type of condition should be treated by initiating prophylactic anti-thrombotic drugs.
The patients who are acquiring this condition then thromboprophylaxis should be provided
Pomalidomide metabolism is mediated by CYP1A2 & CYP3A4.
The concomitant use of Pomahope 3mg with CYP1A2 drugs like Fluvoxamine causes elevation of Cmax& AUC of Pomalidomide and concludes as increased concentration of Pomahope leads to higher extent of adverse effects associated with Pomalid
In this condition, reduce the dose of Pomahope 3mg and recommended.
Pomahope 3mg should be contraindicated to pregnancy & lactating women. The pregnancy category of Pomahope 3mg is X.
More common effects of Pomahope 3mg :
If taken during pregnancy, Severe life-threatening human birth defects
Low white blood cell count
Shortness of breath
Upper respiratory infections
Less common effects of Pomahope 3mg